Protagonist Therapeutics director sells 12,000 after exercising 12,000

Q: What insider activity did PTGX disclose on Form 4?

Director William D. Waddill exercised 12,000 options at $6.98 and sold 12,000 shares on 10/10/2025 .

Q: At what prices were PTGX shares sold?

Sales were 4,000 shares at $69.25 and 8,000 shares at a $87.81 weighted average (range $86.71–$88.00 ).

Q: How many PTGX shares does the director hold after the transactions?

He directly holds 5,130 shares after the reported transactions.

Q: Was the PTGX sale under a Rule 10b5-1 plan?

Yes. Sales were effected under a Rule 10b5-1 trading plan adopted on November 10, 2023 .

Q: What is the status of the exercised options?

The 12,000 stock options were fully vested and had an expiration date of 05/28/2028 .

Filing Impact

(High)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

Protagonist Therapeutics (PTGX) director William D. Waddill exercised 12,000 stock options at $6.98 on 10/10/2025 and sold 12,000 shares the same day pursuant to a Rule 10b5-1 trading plan adopted on November 10, 2023.

Sales included 4,000 shares at $69.25 and 8,000 shares at a $87.81 weighted average, with individual trades ranging from $86.71 to $88.00. Following these transactions, he directly holds 5,130 shares. The exercised options were fully vested and were set to expire on 05/28/2028.

Insider Trade Summary

Net Seller: 12,000 shares ($979,480)

Net Sell 4 txns

Insider Waddill William D.

Role Director

Sold 12,000 shs ($979K)

Type	Security	Shares	Price	Value
Exercise	Stock Option (right to buy)	12,000	$0.00	--
Exercise	Common Stock	12,000	$6.98	$84K
Sale	Common Stock	4,000	$69.25	$277K
Sale	Common Stock	8,000	$87.81	$702K

Holdings After Transaction: Stock Option (right to buy) — 0 shares (Direct); Common Stock — 17,130 shares (Direct)

Footnotes (1)

Sale of shares effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 10, 2023. The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $86.71 to $88.00. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. These stock options are fully vested.

Form 4 Insider Transactions: What Each Field Means →

10/14/2025 - 04:01 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Waddill William D.

(Last)

(First)

(Middle)

C/O PROTAGONIST THERAPEUTICS, INC.

7707 GATEWAY BLVD., SUITE 140

(Street)

NEWARK

94560-1160

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Protagonist Therapeutics, Inc [ PTGX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
10/10/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	10/10/2025		M		12,000	A	$6.98	17,130	D
Common Stock	10/10/2025		S⁽¹⁾		4,000	D	$69.25	13,130	D
Common Stock	10/10/2025		S⁽¹⁾		8,000	D	$87.81⁽²⁾	5,130	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (right to buy)	$6.98	10/10/2025		M			12,000	⁽³⁾	05/28/2028	Common Stock	12,000	$0.00	0	D

Explanation of Responses:

1. Sale of shares effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 10, 2023.

2. The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $86.71 to $88.00. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.

3. These stock options are fully vested.

	/s/ Matthew Gosling, Attorney-in-Fact for William D. Waddill	10/14/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider activity did PTGX disclose on Form 4?

Director William D. Waddill exercised 12,000 options at $6.98 and sold 12,000 shares on 10/10/2025.

At what prices were PTGX shares sold?

Sales were 4,000 shares at $69.25 and 8,000 shares at a $87.81 weighted average (range $86.71–$88.00).

How many PTGX shares does the director hold after the transactions?

He directly holds 5,130 shares after the reported transactions.

Was the PTGX sale under a Rule 10b5-1 plan?

Yes. Sales were effected under a Rule 10b5-1 trading plan adopted on November 10, 2023.

What were the Form 4 transaction codes?

Code M for the option exercise and code S for the open-market sales.

What is the status of the exercised options?

The 12,000 stock options were fully vested and had an expiration date of 05/28/2028.